Denmark, March 13, 2015.
Come and meet us at the following Nordic Emergency meetings, where we will be present together with our Nordic distributor Electra-box Diagnostica:
March 16-17: SWEET 2015 - National meeting of Swedish Society for Emergency Medicine and the Nordic Federation of Emergency Meeting in Stockholm, Sweden.
Visit us at booth no. 7 where we will be running demos of the suPARnostic® Quick Triage product.
Hear the oral presentation by Dr. Jesper Eugen-Olsen, Denmark, on
Monday, March 16, at 12.40 - 12.55
See the Poster presentation by Dr. Jesper Eugen-Olsen, Denmark, in SEGLORA hall,
Tuesday, March 17th at 9.10 - 10.10 with the topic:
"suPAR is associated with comorbidities, disease severity, readmission, and mortality in the acute medical patient"
Please find the poster here: SWEET 2015 - Hvidovre Hospital Poster
March 17-18: SAM 2015 - Skandinavisk Akuttmedisin 2015 in Trondheim, Norway.
Visit us at booth no. 2 where we will be running demos of the suPARnostic® Quick Triage product during the coffee breaks:
Tuesday, March 17:
11.00 - 11.30
16.00 - 16.30
Wednesday, March 18:
09.15 - 09.30
11.00 - 11.30
Looking forward to tell you more about suPARnostic® in early triage!
Denmark, February 25, 2015.
ViroGates A/S, the leading provider of products for triaging patients in acute care, today announced the appointment of Lars Kongsbak and Bernd Uder as new members of the Board of Directors.
Effective immediately, the new Board of Directors will consist of Lars Kongsbak, who will serve as chairman, Bernd Uder and Jørgen Thorball.
ViroGates’ suPARnostic® product enables healthcare physicians to triage patients in acute care by assessing which patients that need to be admitted to the hospital wards and which patients can be dismissed.
The suPARnostic® blood based test has been extensively validated in the clinical settings around the world and addresses an unmet need for products to objectively prioritise patients admitted to the emergency room.
Denmark, February 19, 2015.
Join us at the 24th Winter Symposium of Emergency Medicine and Intensive Care in Karpacz, Poland!
The Symposium will take place on February 25-28, 2015.
Our distributor Biomedica will be representing suPARnostic at their booth.
Hear the oral presentation by Dr. Jesper Eugen-Olsen, Hvidovre Hospital, Denmark:
"Implementation of suPAR in clinical routine: Association with disease severity, readmission, and mortality in the acute medical patient"
The presentation will take place in Panel Session 3 on Friday, Feb. 27th between 9:00-11:00.
Denmark, January 13, 2015.
76 new articles on suPAR were published in PubMed in 2014.
Thus we can now celebrate more than 330 publications in total on suPARnostic® * being a prognostic biomarker for survival in various diseases such as Cardiovascular diseases, Infectious diseases, Inflammation, Sepsis, Nephrology conditions, different Cancers, Diabetes, etc.
To view the full publication list in PubMed and refine your own search - Please click here
To visit our database-file where you can find the publications listed either by date or grouped by organ and disease - Please click here
Denmark, December 1, 2014.
New data from the first Danish Interventional Study done in Hillerød University Hospital in Denmark and based on 6000 patients was presented at the 6´th Danish Emergency Medicine Conference in November, 2014.
Data are based on all medical patients coming to the Emergency Room (ER), and are thus very representative for the most common diseases seen in any Emergency Room incl. not only bacterial or viral infections but also CVD, cardiac cases, lung diseases and comorbidities.
The poster titled "suPAR - A future prognostic biomarker in Emergency Medicine" was awarded a prize because of the solid study design and the diligence with which the data was collected, calculated and presented.
Data shows that the current Danish Emergency Process triage system needs to be improved with a prognostic biomarker evaluation - and suPAR is the best choice!
The conclusion is clear:
"In unselected patients admitted to an Emergency Department, suPAR is an independant marker of short-term mortality.
suPAR could potentially help clinicians in the initial risk assessment of acutely admitted patients".